Cargando…
Association of a Palliative Surgical Approach to Stage IV Pancreatic Neuroendocrine Neoplasms with Survival: A Systematic Review and Meta-Analysis
The role of primary tumor resection in patients with pancreatic neuroendocrine neoplasms (PanNENs) and unresectable distant metastases remains controversial. We aimed to evaluate the effect of palliative primary tumor resection (PPTR) on overall survival (OS) in this setting. We searched the MEDLINE...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464632/ https://www.ncbi.nlm.nih.gov/pubmed/32796714 http://dx.doi.org/10.3390/cancers12082246 |
_version_ | 1783577408105873408 |
---|---|
author | Tsoli, Marina Spei, Maria-Eleni Wallin, Göran Kaltsas, Gregory Daskalakis, Kosmas |
author_facet | Tsoli, Marina Spei, Maria-Eleni Wallin, Göran Kaltsas, Gregory Daskalakis, Kosmas |
author_sort | Tsoli, Marina |
collection | PubMed |
description | The role of primary tumor resection in patients with pancreatic neuroendocrine neoplasms (PanNENs) and unresectable distant metastases remains controversial. We aimed to evaluate the effect of palliative primary tumor resection (PPTR) on overall survival (OS) in this setting. We searched the MEDLINE, Embase, Cochrane Library, Web of Science and SCOPUS databases up to January 2020 and used the Newcastle–Ottawa scale (NOS) criteria to assess quality/risk of bias. A total of 5661 articles were screened. In 10 studies, 5551 unique patients with stage IV PanNEN and unresectable metastases were included. The five-year OS for PanNEN patients undergoing PPTR in stage IV was 56.6% vs. 23.9% in the non-surgically treated patients (random effects relative risk (RR): 1.70; 95% CI: 1.53–1.89). Adjusted analysis of pooled hazard ratios (HR) confirmed longer OS in PanNEN patients undergoing PPTR (random effects HR: 2.67; 95% CI: 2.24–3.18). Cumulative OS analysis confirmed an attenuated survival benefit over time. The complication rate of PPTR was as high as 27%. In conclusion, PPTR may exert a survival benefit in stage IV PanNEN. However, the included studies were subject to selection bias, and special consideration should be given to PPTR anchored to a multimodal treatment strategy. Further longitudinal studies are warranted, with long-term follow-up addressing the survival outcomes associated with surgery in stage IV disease. |
format | Online Article Text |
id | pubmed-7464632 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74646322020-09-04 Association of a Palliative Surgical Approach to Stage IV Pancreatic Neuroendocrine Neoplasms with Survival: A Systematic Review and Meta-Analysis Tsoli, Marina Spei, Maria-Eleni Wallin, Göran Kaltsas, Gregory Daskalakis, Kosmas Cancers (Basel) Review The role of primary tumor resection in patients with pancreatic neuroendocrine neoplasms (PanNENs) and unresectable distant metastases remains controversial. We aimed to evaluate the effect of palliative primary tumor resection (PPTR) on overall survival (OS) in this setting. We searched the MEDLINE, Embase, Cochrane Library, Web of Science and SCOPUS databases up to January 2020 and used the Newcastle–Ottawa scale (NOS) criteria to assess quality/risk of bias. A total of 5661 articles were screened. In 10 studies, 5551 unique patients with stage IV PanNEN and unresectable metastases were included. The five-year OS for PanNEN patients undergoing PPTR in stage IV was 56.6% vs. 23.9% in the non-surgically treated patients (random effects relative risk (RR): 1.70; 95% CI: 1.53–1.89). Adjusted analysis of pooled hazard ratios (HR) confirmed longer OS in PanNEN patients undergoing PPTR (random effects HR: 2.67; 95% CI: 2.24–3.18). Cumulative OS analysis confirmed an attenuated survival benefit over time. The complication rate of PPTR was as high as 27%. In conclusion, PPTR may exert a survival benefit in stage IV PanNEN. However, the included studies were subject to selection bias, and special consideration should be given to PPTR anchored to a multimodal treatment strategy. Further longitudinal studies are warranted, with long-term follow-up addressing the survival outcomes associated with surgery in stage IV disease. MDPI 2020-08-11 /pmc/articles/PMC7464632/ /pubmed/32796714 http://dx.doi.org/10.3390/cancers12082246 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Tsoli, Marina Spei, Maria-Eleni Wallin, Göran Kaltsas, Gregory Daskalakis, Kosmas Association of a Palliative Surgical Approach to Stage IV Pancreatic Neuroendocrine Neoplasms with Survival: A Systematic Review and Meta-Analysis |
title | Association of a Palliative Surgical Approach to Stage IV Pancreatic Neuroendocrine Neoplasms with Survival: A Systematic Review and Meta-Analysis |
title_full | Association of a Palliative Surgical Approach to Stage IV Pancreatic Neuroendocrine Neoplasms with Survival: A Systematic Review and Meta-Analysis |
title_fullStr | Association of a Palliative Surgical Approach to Stage IV Pancreatic Neuroendocrine Neoplasms with Survival: A Systematic Review and Meta-Analysis |
title_full_unstemmed | Association of a Palliative Surgical Approach to Stage IV Pancreatic Neuroendocrine Neoplasms with Survival: A Systematic Review and Meta-Analysis |
title_short | Association of a Palliative Surgical Approach to Stage IV Pancreatic Neuroendocrine Neoplasms with Survival: A Systematic Review and Meta-Analysis |
title_sort | association of a palliative surgical approach to stage iv pancreatic neuroendocrine neoplasms with survival: a systematic review and meta-analysis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464632/ https://www.ncbi.nlm.nih.gov/pubmed/32796714 http://dx.doi.org/10.3390/cancers12082246 |
work_keys_str_mv | AT tsolimarina associationofapalliativesurgicalapproachtostageivpancreaticneuroendocrineneoplasmswithsurvivalasystematicreviewandmetaanalysis AT speimariaeleni associationofapalliativesurgicalapproachtostageivpancreaticneuroendocrineneoplasmswithsurvivalasystematicreviewandmetaanalysis AT wallingoran associationofapalliativesurgicalapproachtostageivpancreaticneuroendocrineneoplasmswithsurvivalasystematicreviewandmetaanalysis AT kaltsasgregory associationofapalliativesurgicalapproachtostageivpancreaticneuroendocrineneoplasmswithsurvivalasystematicreviewandmetaanalysis AT daskalakiskosmas associationofapalliativesurgicalapproachtostageivpancreaticneuroendocrineneoplasmswithsurvivalasystematicreviewandmetaanalysis |